Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Acorda Therapeutics (ACOR)

Acorda Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACOR
DateTimeSourceHeadlineSymbolCompany
15/04/202422:03Business WireAcorda Therapeutics Announces Delisting from NasdaqNASDAQ:ACORAcorda Therapeutics Inc
03/04/202422:30Business WireAcorda Therapeutics Announces Nasdaq Delisting NotificationNASDAQ:ACORAcorda Therapeutics Inc
01/04/202423:35Business WireAcorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase AgreementNASDAQ:ACORAcorda Therapeutics Inc
01/04/202421:01Business WireAcorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024NASDAQ:ACORAcorda Therapeutics Inc
25/03/202420:01Business WireAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024NASDAQ:ACORAcorda Therapeutics Inc
11/01/202413:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACORAcorda Therapeutics Inc
11/01/202413:01Business WireAcorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025NASDAQ:ACORAcorda Therapeutics Inc
01/12/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACORAcorda Therapeutics Inc
13/11/202321:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACORAcorda Therapeutics Inc
13/11/202321:01Business WireAcorda Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:ACORAcorda Therapeutics Inc
06/11/202321:01Business WireAcorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023NASDAQ:ACORAcorda Therapeutics Inc
06/11/202313:00Business WireAcorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®NASDAQ:ACORAcorda Therapeutics Inc
08/08/202321:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACORAcorda Therapeutics Inc
08/08/202321:01Business WireAcorda Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:ACORAcorda Therapeutics Inc
02/08/202313:00Business WireAcorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”NASDAQ:ACORAcorda Therapeutics Inc
01/08/202313:00Business WireAcorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023NASDAQ:ACORAcorda Therapeutics Inc
28/06/202322:08Business WireTom Burns Elected to the Acorda Therapeutics Board of DirectorsNASDAQ:ACORAcorda Therapeutics Inc
26/06/202321:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACORAcorda Therapeutics Inc
26/06/202313:23Business WireAcorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:ACORAcorda Therapeutics Inc
26/06/202313:00Business WireAcorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price RequirementNASDAQ:ACORAcorda Therapeutics Inc
23/06/202322:39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACORAcorda Therapeutics Inc
23/06/202322:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACORAcorda Therapeutics Inc
23/06/202322:37Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACORAcorda Therapeutics Inc
23/06/202322:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACORAcorda Therapeutics Inc
02/06/202321:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACORAcorda Therapeutics Inc
02/06/202321:01Business WireAcorda Therapeutics Announces Completion of 1-for-20 Reverse Stock SplitNASDAQ:ACORAcorda Therapeutics Inc
01/06/202322:17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACORAcorda Therapeutics Inc
31/05/202322:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACORAcorda Therapeutics Inc
31/05/202321:01Business WireAcorda Therapeutics to Conduct 1-for-20 Reverse Stock SplitNASDAQ:ACORAcorda Therapeutics Inc
30/05/202313:00Business WireAcorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&ANASDAQ:ACORAcorda Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACOR